抗寄生虫药物市场- 按药物类型（驱虫药、抗原虫药、杀体外寄生虫药）、给药途径（注射剂、口服、局部用药）、最终用户（医院药房、零售药房、在线药房）、全球预测（2024年至2032年）

Antiparasitic Drugs Market - By Drug Type (Anthelmintics, Antiprotozoal, Ectoparasiticide), Route of Administration (Injectable, Oral, Topical), End User (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Global Forecast (2024 - 2032)

出版日期: 2024年02月06日 | 出版商:

Global Market Insights Inc. | 英文 110 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2024 年至 2032 年，全球抗寄生虫药物市场规模将呈现 5.7% 的CAGR，这得益于全国分销管道的可及性以及多样化的选择。这种广泛的可用性确保了不同地区的个人能够轻鬆获得基本药物，从而更有效地解决全球寄生虫疾病的负担。由于有多种选择，医疗保健提供者和患者可以灵活地选择最合适的治疗方法，进一步促进行业扩张。例如，2022 年 3 月，May & Baker尼日利亚公司。推出了 Artelum Combo，这是一种针对疟原虫的新型药物，在全国推广，旨在解决该国的疟疾负担。

抗寄生虫药物市场根据药物类型、给药途径、最终用户和地区进行细分。

根据给药途径，到 2032 年，口服药物的行业份额将获得 6% 的CAGR。口服药物的便利性和有效性使其成为患者和医疗保健提供者的首选。口服製剂也易于给药，提高患者依从性，吸收更快，从而更快地缓解寄生虫感染。随着口服给药技术的不断进步和多种口服抗寄生虫药物的出现，对口服解决方案的需求将会增长，以应对寄生虫疾病带来的全球挑战。

就最终用户而言，到 2032 年，零售药房领域的抗寄生虫药物市场CAGR将达到 6.2%，这得益于消费者获得药物的便捷性以及零售药房在当地社区的广泛存在。最近，寻求抗寄生虫药物的患者开始转向零售药局以获得方便的采购和专业建议。此外，自我药疗和非处方药销售的成长趋势将提高人们对这些药局的偏好，以提供解决寄生虫感染的便利性和可及性。

由于寄生虫感染发生率上升、医疗基础设施扩大以及对治疗选择的认识不断提高，亚太地区抗寄生虫药物行业规模到 2032 年将实现 6.8% 的CAGR。中国、印度和日本等国家处于领先地位，对这些药物的需求量很大。此外，政府旨在根除寄生虫病的措施也有所增加。凭藉其多样化的景观和庞大的医疗保健需求，亚太地区将成为全球抗寄生虫药物产业的主要贡献者。

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 中东和非洲其他地区

第 9 章：公司简介

Bayer AG
Cipla Inc.
Dr. Reddy's Laboratories Ltd,
GlaxoSmithKline plc
Glenmark Pharmaceuticals Ltd
Ipca Laboratories Ltd.
Mankind Pharma
Merck KGaA
Novartis AG
Sanofi
Zydus Group

简介目录

Product Code: 8043

Global Antiparasitic Drugs Market size will demonstrate 5.7% CAGR from 2024 to 2032, driven by their accessibility through nationwide distribution channels coupled with the diverse range of options. This widespread availability ensures that individuals in various regions can easily access essential medications for addressing the global burden of parasitic diseases more effectively. With a multitude of choices available, healthcare providers and patients have the flexibility to select the most suitable treatments, further contributing to the industry expansion. For instance, in March 2022, May & Baker Nigeria Plc. introduced Artelum Combo, a novel medication targeting malaria parasites, with a nationwide rollout aimed at addressing the country's malaria burden.

The antiparasitic drugs market is segmented on the basis of drug type, route of administration, end-user, and region.

Based on route of administration, the industry share from the oral segment will gain 6% CAGR up to 2032. The convenience and effectiveness of oral medications is making them a preferred choice for patients and healthcare providers. Oral formulations also offer ease of administration, improved patient compliance, and quicker absorption, leading to faster relief from parasitic infections. With rising advancements in oral drug delivery technologies and a wide range of oral antiparasitic options available, the need for oral solutions will grow for tackling global challenges posed by parasitic diseases.

In terms of end-user, the antiparasitic drugs market from the retail pharmacy segment will experience 6.2% CAGR through 2032, propelled by convenient access to medications for consumers coupled with the widespread presence of retail pharmacies in local communities. Of late, patients seeking antiparasitic remedies are turning to retail pharmacies for easy procurement and professional advice. Moreover, the rising trend of self-medication and over-the-counter sales will boost the preference for these pharmacies to render convenience and accessibility in addressing parasitic infections.

Asia Pacific antiparasitic drugs industry size will secure a 6.8% CAGR up to 2032, driven by rising incidences of parasitic infections, expanding healthcare infrastructure, and the increasing awareness about treatment options. Countries like China, India, and Japan are at the forefront, witnessing substantial demand for these medications. Additionally, there has been a rise in government initiatives aimed at eradicating parasitic diseases. With its diverse landscape and significant healthcare needs, the APAC region will emerge as a major contributor to the global antiparasitic drugs industry.

Chapter 1 Methodology& Scope

1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast calculation
1.5 Data validation
1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Public sources

Chapter 2 Executive Summary

2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising prevalence of parasitic infections
  - 3.2.1.2 Increasing government initiatives and funding
  - 3.2.1.3 Increasing global travel and migration
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Increasing drug resistance
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
- 3.5.1 Supplier power
- 3.5.2 Buyer power
- 3.5.3 Threat of new entrants
- 3.5.4 Threat of substitutes
- 3.5.5 Industry rivalry
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Drug Type, 2018 - 2032 ($ Mn)

5.1 Key trends
5.2 Anthelmintics
5.3 Antiprotozoal
5.4 Ectoparasiticides
5.5 Other drug types

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2018 - 2032 ($ Mn)

6.1 Key trends
6.2 Injectable
6.3 Oral
6.4 Topical

Chapter 7 Market Estimates and Forecast, By End-User, 2018 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospital pharmacy
7.3 Retail pharmacy
7.4 Online pharmacy

Chapter 8 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 Rest of Middle East and Africa